Protara Therapeutics – Tackling the Unmet Need in Bladder Cancer and the company’s investigational cell therapy, TARA-002
Dr. Jathin Bandari, MD, Chief Medical Officer at Protara Therapeutics, a clinical-stage company committed to identifying and advancing transformative therapies for people with cancer and rare diseases, discusses non-muscle invasive bladder cancer (NMIBC) and the company’s investigational cell therapy, TARA-002, that is currently in development for the treatment of NMIBC, which Protara believes can help address the pressing unmet need for the treatment of this form of bladder cancer.
Jathin Bandari, M.D. joined Protara in April 2020 and has served as Chief Medical Officer since January 2022. He previously served as Vice President, Head of Clinical Development, Interim Chief Medical Officer. He is a Urologic Oncologist who specializes in both minimally invasive urologic oncology and advanced open pelvic and retroperitoneal cancer surgery. Dr. Bandari received his medical degree at Johns Hopkins University and completed his urology residency at University of Pittsburgh Medical Center. Following residency, he completed a Society of Urologic Oncology fellowship at the University of Pittsburgh Medical Center. He is an active member of the American Urological Association, Society of Urologic Oncology, American Society of Clinical Oncology, and Southwest Oncology Group. He has over 50 authorships, national speakerships, textbooks, and grants. He maintains an academic appointment at the University of Rochester.
